Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Offloading Biosimilars To Biocon ‘First Step’ Towards Viatris’ $9bn Target

Viatris On ‘Clear Path’ To Building In Generics And Complex Generics

Executive Summary

After confirming rumors that it would offload its biosimilars unit to its long-term partner Biocon, Viatris has outlined plans to add to the expected cash proceeds with other divestments to complete on several strategic goals up to 2023. Bumping up R&D spending to facilitate complex generic launches is a continued priority for the company.

You may also be interested in...

Stick, Twist Or Split? Generics Industry’s Big Three Place Their Bets

With Teva and Viatris recently under new management and Sandoz having last year split from former parent company Novartis, the three off-patent industry leaders are adopting different strategies for how they balance their generics and biosimilars interests with more innovative ventures.

Malik To Step Down As Viatris President Amid Continuing Strategic Shift

Rajiv Malik is to retire as president of Viatris from 1 April 2024, amid a continuing strategic transformation for the business that was formed by the merger of Mylan and Pfizer’s Upjohn.

Viatris Finds A Buyer For India API Business, Other Assets, Ushering In New Era

Viatris underlined a bold new vision early in 2022 when it announced the sale of its global biosimilars business to Biocon Biologics. Now it has moved to sell its remaining non-core units.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts